lifileucel · Amtagvi

Cell therapy

Approvedregulatory verdict

Evidence outlook

Approved: Melanoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (2)
AU
  • Adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody (and BRAF/MEK inhibitor if BRAF V600 positive); approval with conditions
Product first approved 2026biospace.com
CA
  • Adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody (and a BRAF inhibitor +/- MEK inhibitor if BRAF V600 positive); Notice of Compliance with Conditions
Product first approved 20251stoncology.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (1)
Melanoma
Phase 2 (6)
Melanoma
NCT07288203 · Iovance Biotherapeutics, Inc.
2025-11-28 – 2028-06 · Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
What this study did
NCT03645928 · Iovance Biotherapeutics, Inc.
2019-05-07 – 2026-02-20 · Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
What this study did
NCT06151847 · University of Kansas Medical Center
2023-12-21 – 2025-07-10 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma
What this study did
Other / comorbidity
NCT07741877 · Iovance Biotherapeutics, Inc.
2026-10-02 – 2034-09-01 · Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)
What this study did
NCT06481592 · Iovance Biotherapeutics, Inc.
2024-10-29 – 2029-11 · Endometrial Cancer
What this study did
Phase 1/2 (1)
Melanoma
NCT06940739 · Iovance Biotherapeutics, Inc.
2025-03-11 – 2032-07 · Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
What this study did
Phase 1 (4)
Melanoma
NCT07700121 · Abramson Cancer Center at Penn Medicine
2026-10-01 – 2029-10-01 · Unresectable or Metastatic Melanoma
What this study did
NCT05640193 · Memorial Sloan Kettering Cancer Center
2022-11-25 – 2027-11 · Metastatic Melanoma
What this study did
NCT05607095 · Memorial Sloan Kettering Cancer Center
2022-11-01 – 2027-05-01 · Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
What this study did
NCT05176470 · Richard Wu
2022-07-01 – 2026-12-31 · Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Stage IV Melanoma
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Melanoma
NCT06743126 · Immatics US, Inc.
2025-01-14 – 2032-08-12 · Melanoma, Cutaneous Malignant, Mucosal Melanoma
What this study did

Competitive landscape

This drug's own stage for Melanoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lifileucel (Amtagvi): this drugApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BinimetinibApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
CobimetinibApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
RelatlimabApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
VemurafenibApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CemiplimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FianlimabPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)Phase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Amtagvi (lifileucel) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
May 2027 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2027-05-01 · NCT05607095 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1MelanomaActive not recruiting
Est. primary completion 2027-11 · NCT05640193 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12 · NCT07288203 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
Phase 3MelanomaRecruiting
Est. primary completion 2028-03-01 · NCT05727904 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Endometrial CancerRecruiting
Est. primary completion 2028-05 · NCT06481592 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1MelanomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT07700121 · CT.gov ↗
What to watch
2032 (1)
June 2032 (1)
Phase 1/2MelanomaRecruiting
Est. primary completion 2032-06 · NCT06940739 · CT.gov ↗
What to watch
2033 (1)
September 2033 (1)
Phase 2Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) …Recruiting
Est. primary completion 2033-09-01 · NCT07741877 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 June 2026ApprovalAmtagvi approved in Australia for advanced melanoma
AU, TGA · Source ↗